What have pharmacies paid for Tenofovir Disoproxil Fumarate since 2013?
What pharmacies pay, not what you pay. Tenofovir Disoproxil Fumarate has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Tenofovir Disoproxil Fumarate 300 MG Tablet: $1.41 per unit at the 2018 survey and $0.296 at 2026 (−79%).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Tenofovir Disoproxil Fumarate1 product in NADAC
1product with a price history
Tenofovir Disoproxil Fumarate has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
Between each product's first and latest year-end survey, 1 product costs pharmacies less and none costs more, by more than 5 percent, per unit as CMS states it.
This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.
Tenofovir Disoproxil Fumarate 300 MG Tablet
Generic
$1.41 per unit at the 2018 year-end survey (10 NDCs) and $0.296 at the 2026 survey (12 NDCs): −79%.
year-end median across the NDCs pricedlowest to highest NDC
Year-end survey
Median per unit
Lowest to highest
NDCs priced
2018 (2018-12-26)
$1.41
10
2019 (2019-12-25)
$0.995
12
2020 (2020-12-30)
$0.949
10
2021 (2021-12-29)
$0.663
9
2022 (2022-12-28)
$0.520
11
2023 (2023-12-27)
$0.455
11
2024 (2024-12-25)
$0.420
11
2025 (2025-12-31)
$0.347
11
2026 (2026-11-11)
$0.296
12
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
Where does Tenofovir Disoproxil Fumarate sit on the generic price cliff?
Tenofovir Disoproxil Fumarate 300 MG Tablet: the first generic approval in its Orange Book group is dated 2015. Its year-end acquisition cost in 2026 is 21% of its first observed year-end price (2018). The median matched product, 11 years after its first generic approval, is at 21% (the middle half runs from 5% to 51%), so this product is inside that middle half.
median of 200 matched productsmiddle halfeach productTenofovir Disoproxil Fumarate 300 MG Tablet
This is a pattern in matched products. It does not say the first generic caused the fall, and it does not say this product's price will follow the median. See it with other drugs.
How many companies make Tenofovir Disoproxil Fumarate?
The FDA Orange Book lists 11 generic makers as marketed in its largest dosage form for Tenofovir Disoproxil Fumarate, and the first generic approval is dated 18 March 2015. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.